Only a small percentage of older adults who are in the early stages of Alzheimer’s disease meet the eligibility criteria to receive new monoclonal antibody treatments, drugs that target amyloid-ß plaques in the brain, an early sign of Alzheimer’s disease.
FDA sets aggressive deadline for inspection overhaul
WASHINGTON — Food and Drug Administration officials hope to finish this year a massive overhaul of the way the agency inspects facilities that make drugs,
January 22, 2024